Becton, Dickinson and Company raised revenue guidance for the full-year 2022. The company now expects fiscal year 2022 revenues to be in the range of approximately $18.75 billion to $18.83 billion compared to $18.5 billion to $18.7 billion previously announced, which reflects an increase of approximately $190 million at the mid-point. Revenue guidance for fiscal year 2022 now assumes base business currency-neutral revenue growth of 8.75% to 9.25% compared to 7.25% to 8.25% previously announced, which represents an increase of approximately 125 basis points, or approximately $215 million at the mid-point.

The revenue guidance range now assumes up to $500 million in COVID-19-only diagnostic testing revenues which is an increase of up to $50 million compared to approximately $450 million previously announced. Based on current rates, foreign exchange would represent a reduction of approximately 225 basis points to total company revenue growth compared to approximately 200 basis points previously announced, which represents an incremental headwind of approximately $50 million.